Dr. RAS Naidu, PhD1. Introduction
Ligand–drug conjugates are targeted therapeutic systems in which a molecular recognition component is chemically linked to a therapeutic or diagnostic payload. The ligand directs the conjugate towards a selected biological target, while the payload produces the intended pharmacological or diagnostic effect.
Unlike conventional ligand-functionalized nanoparticles, many ligand–drug conjugates do not require a separate particulate carrier. Instead, the targeting molecule, linker, and payload form a defined molecular construct. Advances in antibody–drug conjugate design and development illustrate the growing importance of this approach in oncology.
Understanding conjugate architecture, payload-release mechanisms, pharmacokinetics, manufacturing requirements, and regulatory considerations helps researchers distinguish molecular conjugates from nanoparticle-based delivery systems.
Message to readers: How can ligand–drug conjugates improve targeted drug delivery beyond conventional nanoparticle-based systems? This article explores the science behind antibody–drug conjugates, peptide–drug conjugates, small-molecule conjugates and radioligand therapeutics, with a focus on ligand selection, linker design, payload delivery, formulation challenges, manufacturing, regulatory considerations and emerging AI applications.
Whether you are a pharmaceutical formulation scientist, drug delivery researcher, regulatory professional or student, this article offers practical insights into the opportunities and limitations of these evolving therapeutic platforms and their journey from molecular design to clinical translation.
Read on, explore the evidence, and share your perspectives: Which design or development challenge do you consider most critical for advancing the next generation of ligand–drug conjugates?
2. Major Types of Ligand–Drug Conjugates
- Antibody–drug conjugates (ADCs): Monoclonal antibodies recognize selected antigens and deliver attached drug payloads. Many marketed ADCs use potent cytotoxic agents.
- Peptide–drug conjugates (PDCs): Target-binding peptides are linked to therapeutic payloads. Their molecular size and pharmacokinetic characteristics can differ from those of antibody-based constructs. Read more about peptide–drug conjugate design, chemistry, and delivery.
- Small-molecule–drug conjugates (SMDCs): Small-molecule ligands recognize selected biological targets and are linked to therapeutic agents.
- Ligand–radionuclide conjugates: Targeting molecules deliver radionuclides to selected tissues. Examples include peptide- and small-molecule-based radiopharmaceuticals.
- Other bioconjugates: Aptamer-, protein-, and other ligand-based constructs are being investigated for targeted delivery, diagnostics, and theranostic applications.
These categories differ in molecular size, target recognition, tissue distribution, payload type, and release requirements. Their clinical maturity also varies.
3. Marketed Examples: Molecular Conjugates Without a Nanoparticle Carrier
Marketed molecular conjugates demonstrate the clinical relevance of ligand-mediated recognition. The following examples illustrate different targeting components and payloads.
| Product | Conjugate platform and payload | Targeting ligand | Main application |
| Mylotarg (gemtuzumab ozogamicin) | ADC; calicheamicin payload | Anti-CD33 antibody | Selected acute myeloid leukaemia |
| Adcetris (brentuximab vedotin) | ADC; MMAE payload | Anti-CD30 antibody | Selected lymphomas |
| Kadcyla (ado-trastuzumab emtansine) | ADC; DM1 payload | Anti-HER2 antibody | HER2-positive breast cancer |
| Enhertu (trastuzumab deruxtecan) | ADC; deruxtecan payload | Anti-HER2 antibody | Selected HER2-expressing cancers |
| Trodelvy (sacituzumab govitecan) | ADC; SN-38 payload | Anti-TROP-2 antibody | Selected cancers, including breast cancer |
| Elahere (mirvetuximab soravtansine) | ADC; DM4 payload | Anti-folate receptor alpha antibody | Selected FRα-positive ovarian cancer |
| Lutathera (lutetium Lu 177 dotatate) | Peptide–radionuclide conjugate | Somatostatin-receptor-binding peptide analogue | Gastroenteropancreatic neuroendocrine tumours |
| Pluvicto (lutetium Lu 177 vipivotide tetraxetan) | Small-molecule–radionuclide conjugate | PSMA-binding small-molecule ligand | Selected PSMA-positive prostate cancer |
Scientific distinction: In ADCs, the antibody serves as the target-recognition component and molecular scaffold for the chemically attached payload. Lutathera and Pluvicto link targeting molecules to radioactive payloads. These products do not use a conventional nanoparticle to encapsulate the therapeutic agent.
By contrast, ligand-functionalized PLGA nanoparticles, liposomes, and lipid nanoparticles can carry drugs within their matrix, core, or lipid structure while presenting targeting ligands on their surfaces.
Product indications and approval status may vary by jurisdiction and change over time. Verify current information using the relevant official product labels.
4. Design Principles: From Ligand Recognition to Payload Delivery
The performance of a ligand–drug conjugate depends on the coordinated behaviour of its principal components.
Target selection: The biological target should be accessible and sufficiently expressed in the intended disease population. Target heterogeneity and expression in healthy tissues may affect selectivity and safety.
Ligand selection: Antibodies offer high-affinity recognition of selected antigens, while peptides and small molecules may provide different tissue-penetration, distribution, and clearance profiles.
Linker design: Linkers must maintain conjugate integrity during circulation while permitting appropriate payload release or activity. Cleavable linkers respond to selected conditions, such as enzymes or intracellular environments; non-cleavable linkers rely on different processing mechanisms.
Payload selection: Payload potency, mechanism of action, stability, and tolerability must suit the intended therapeutic effect.
Conjugation strategy: The attachment site and chemical method can influence product heterogeneity, aggregation, stability, and biological activity. Drug-to-antibody ratio is particularly important for ADCs. Research on homogeneous multi-payload antibody–drug conjugates illustrates the importance of controlling conjugate architecture and payload composition.
These components cannot be optimized independently. Changes in linker chemistry or payload loading may alter pharmacokinetics, safety, and therapeutic performance.
5. Pharmacokinetics, Safety and Clinical Translation
Ligand-mediated recognition can improve delivery to selected targets, but it does not guarantee exclusive localization or freedom from toxicity.
Potential limitations include target heterogeneity, inadequate tissue penetration, premature payload release, rapid clearance, immunogenicity, off-target binding, and acquired resistance. For ADCs, toxicity may arise from the payload, linker instability, target expression in normal tissues, or other biological mechanisms.
PDCs and small-molecule conjugates may have different distribution and clearance profiles from antibody-based constructs. Radioligand therapies introduce additional considerations, including radionuclide stability, radiation exposure, dosimetry, and protection of non-target tissues.
Clinical translation therefore requires integrated evaluation of pharmacokinetics, pharmacodynamics, target engagement, dose–response relationships, safety, and patient-selection biomarkers.
6. Molecular Conjugates Versus Ligand-Functionalized Nanoparticles
| Feature | Molecular conjugates | Ligand-functionalized nanoparticles |
| Basic architecture | Ligand, linker, and payload form a molecular construct | A particulate carrier presents ligands on its surface |
| Drug association | Commonly chemical attachment | Encapsulation, matrix incorporation, lipid association, or chemical attachment |
| Key quality attributes | Identity, linker stability, payload ratio, molecular heterogeneity | Particle size, distribution, surface properties, drug loading, ligand density |
| Development focus | Molecular design, conjugation, payload release, pharmacokinetics | Formulation, colloidal stability, release, surface engineering, manufacturing |
The distinction is important: a molecular conjugate links the payload to a targeting construct, whereas a nanoparticle may carry multiple drug molecules within a delivery platform. Hybrid systems can combine both approaches, so classification should follow the actual product architecture.
For the underlying principles of receptor-mediated uptake, ligand selection, and nanoparticle surface engineering, see Ligand-Functionalized Nanoparticles: Active Targeting. Replace this example URL with the exact published permalink if it differs.
7. Role of Artificial Intelligence
Artificial intelligence (AI) and machine learning may support target prioritization, ligand design, linker and payload selection, structure–activity analysis, and prediction of pharmacokinetic or toxicity risks.
In development and manufacturing, data analytics may help identify relationships between conjugation parameters, product heterogeneity, stability, and biological activity. However, predictions require experimental confirmation, representative data, appropriate validation, and documented oversight.
AI should complement medicinal chemistry, analytical characterization, pharmacology, and regulatory assessment rather than replace them.
8. Manufacturing, Quality and Regulatory Considerations
Molecular conjugates require product-specific quality strategies. Relevant attributes may include identity, purity, unconjugated components, payload ratio, linker integrity, aggregation, potency, stability, and biological activity. For radiopharmaceuticals, radionuclidic identity, radiochemical purity, activity, and dosimetry-related controls are also important.
Manufacturing processes must control conjugation reactions, removal of process-related impurities, batch consistency, and storage conditions.
The US FDA’s Clinical Pharmacology Considerations for Antibody-Drug Conjugates guidance provides guidance relevant to ADC development. Requirements for other conjugate classes may differ. Developers should consult current product-specific guidance and the relevant regulatory authority.
9. Conclusion
Ligand–drug conjugates represent an important class of targeted therapeutics in which molecular recognition is linked to a therapeutic or diagnostic payload. ADCs and targeted radiopharmaceuticals have established clinical applications, while peptide- and small-molecule-based conjugates continue to expand the field.
Successful development depends on coordinated ligand, linker, and payload design; reliable manufacturing; robust analytical characterization; and evidence of clinical benefit. Although molecular conjugates and ligand-functionalized nanoparticles share the principle of targeted delivery, their architectures and quality requirements differ substantially.
10. Key Takeaways
- Ligand–drug conjugates combine target recognition with a chemically attached therapeutic or diagnostic payload.
- ADCs, PDCs, small-molecule conjugates, and radioligand conjugates differ in structure and pharmacological behaviour.
- Linker stability, payload characteristics, conjugation chemistry, and target biology influence performance.
- Molecular conjugates are distinct from nanoparticles that encapsulate or carry drugs.
- AI can support design and development but requires experimental validation.
- Quality control and regulatory planning should reflect the specific conjugate architecture.
11. Frequently Asked Questions
Are all ligand–drug conjugates nanoparticles?
No. Many are molecular constructs in which a ligand is chemically linked to a payload without a separate nanoparticle carrier.
What is the role of a linker?
It connects the ligand and payload, helping control conjugate stability and, where relevant, payload release.
Are peptide–drug conjugates the same as antibody–drug conjugates?
No. They use different targeting components and can have distinct tissue distribution, clearance, and manufacturing requirements.
Can molecular conjugates and nanoparticles be combined?
Yes. Hybrid systems can incorporate molecular targeting constructs into nanoparticle platforms, but their architecture and quality attributes must be evaluated specifically.
Disclaimer:
This article is intended for scientific and educational purposes only and does not constitute medical advice, regulatory advice, or a recommendation to use any specific product. Product approvals and indications may vary by jurisdiction and change over time. Readers should consult current official regulatory sources and qualified professionals before making clinical, development, or regulatory decisions.
Related Articles
- Ligand-Functionalized Nanoparticles: Active Targeting — targeting mechanisms and nanoparticle surface design.
- Mannan-Targeted Nanoparticles: From Molecular Design to Clinical Translation — planned specialized article on mannan-based nanoparticle systems.
